Carl Sterritt, chief executive of (), tells Proactive London's Andrew Scott that Feraccru, its iron deficiency drug, has proved itself to be just as good as the current standard of care treatment in a late-stage trial.
The year-long phase IIIb study confirmed Feraccru’s “non-inferiority” to Ferinject when it came to boosting patients’ haemoglobin (Hb) levels.
As part of its commercialisation agreement with Norgine BV, Shield will now receive a €2.5mln milestone payment.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
